Bioequivalence Study on Pseudoephedrine HCl 120 mg ER Tablets Under Fasting Conditions

This study has been completed.
Sponsor:
Information provided by:
Ranbaxy Inc.
ClinicalTrials.gov Identifier:
NCT00779831
First received: October 23, 2008
Last updated: NA
Last verified: October 2008
History: No changes posted
  Purpose

Compare bioavailability of Pseudoephedrine hydrochloride extended release tablets (Ranbaxy Laboratories Limited) against reference product Sudafed ® 12-hour tablets 120 mg (Warner-Lambert) under fasting conditions.


Condition Intervention
Healthy
Drug: 120 mg Pseudoephedrine hydrochloride extended release tablets

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: Comparative, Randomized, Single Dose, 2 Way Crossover Bioavailability Study of Ranbaxy and Warner - Lambert (Sudafed ® 12 Hour) 120 mg Pseudoephedrine Hydrochloride Extended - Release Tablets in Healthy Adult Volunteers Under Fasting Conditions.

Resource links provided by NLM:


Further study details as provided by Ranbaxy Inc.:

Primary Outcome Measures:
  • Bioequivalence [ Designated as safety issue: No ]

Enrollment: 36
Study Start Date: June 2004
Study Completion Date: December 2004
Primary Completion Date: June 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
120 mg Pseudoephedrine hydrochloride extended release tablets of ranbaxy
Drug: 120 mg Pseudoephedrine hydrochloride extended release tablets
Active Comparator: 2
(Sudafed ® 12 hour) 120 mg Pseudoephedrine hydrochloride extended - release tablets
Drug: 120 mg Pseudoephedrine hydrochloride extended release tablets

Detailed Description:

This was an open label, randomized, single dose, 2-way crossover, relative bioavailability study performed on a total of 36 healthy adult subjects (20 males and 16 females). Thirty five (35) subjects (19 males and 16 females) completed the clinical phase of the study. In each period, subjects were housed from at least 10 hours before dosing until after the 36 hour blood draw. Single oral 120 mg Pseudoephedrine hydrochloride doses were separated by a washout period of 7 days.

A total of thirty six (36) subjects (20 males and 16 females) were enrolled in the study. Out of which a total of thirty five (35) subjects (19 males and 16 females) completed the clinical phase of the study.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • All subjects enrolled in this study met all inclusion and exclusion criteria, and were judged by the investigator to be normal, healthy volunteers

Subjects were included in the study if they met all of the following criteria:

  1. Healthy adult male or female volunteers , 18 to 55 years of age
  2. Weighing at least 52 kg for males and 45 kg for females and within 15% of their ideal weights (table of 'Desirable Weights of Adults', Metropolitan Life Insurance Company, 1983)
  3. Medically healthy subjects with clinically normal laboratory profiles and ECGs
  4. Females of child bearing potential should either be sexually inactive (abstinent) for 14 days prior to the first dose and throughout the study or be using one of the following acceptable birth control methods:

    1. Surgically sterile (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) 6 months minimum
    2. IUD in place for at least 3 months
    3. Barrier methods (condom, diaphragm) with spermicide for at least 14 days prior to the first dose and throughout the study
    4. Surgical sterilization of the partner (vasectomy for 6 months minimum)
    5. Hormonal contraceptives for at least 3 months prior to the first dose of the study
    6. Other birth control methods may be deemed acceptable
  5. Post menopausal women with amenorrhea for at least 2 years will be eligible
  6. Voluntarily consent to participate in the study

Exclusion Criteria:

  • Subjects were excluded from the study if there was evidence of any of the following at screening or at any time during the study:

    1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
    2. In addition, history or presence of:

      1. Alcoholism or drug abuse within the past year
      2. Hypersensitivity or idiosyncratic reaction to Pseudoephedrine or any other sympathomimetic amines
      3. Glaucoma or hypermetropia
    3. Female subjects who are pregnant or lactating
    4. Positive results on HIV, HbsAg and HCV tests
    5. Subjects receiving a monoamine oxidase (MAO) inhibitor or within 14 days of stopping use of an MAO inhibitor, or any sympathomimetic amines
    6. Subjects who have been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study
    7. Subjects who through completion of the study, would have donated in excess of:
  • 500 mL of blood in 14 days
  • 1500 mL of blood in 180 days
  • 2500 mL of blood in 1 year. 8. Subjects who have participated in another clinical trial within 28 days prior to the first dose.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00779831

Locations
Canada, Quebec
MDS Pharma Services
Saint-Laurent, Quebec, Canada, H4R2N6
Sponsors and Collaborators
Ranbaxy Laboratories Limited
  More Information

Additional Information:
No publications provided

Responsible Party: Dr. Tausif Monif, Ranbaxy Research labs
ClinicalTrials.gov Identifier: NCT00779831     History of Changes
Other Study ID Numbers: AA16795
Study First Received: October 23, 2008
Last Updated: October 23, 2008
Health Authority: Canada: Health Canada

Keywords provided by Ranbaxy Inc.:
Bioequivalence Pseudoephedrine hydrochloride 120 mg extended release tablets

Additional relevant MeSH terms:
Ephedrine
Pseudoephedrine
Adrenergic Agents
Anti-Asthmatic Agents
Autonomic Agents
Bronchodilator Agents
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Stimulants
Molecular Mechanisms of Pharmacological Action
Nasal Decongestants
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Sympathomimetics
Therapeutic Uses
Vasoconstrictor Agents

ClinicalTrials.gov processed this record on October 29, 2014